Pfizer Inc., of New York, disclosed detailed results from the Oral treatment Psoriasis Trial (OPT) Retreatment study (A3921111), a phase III trial investigating the oral Janus kinase inhibitor tofacitinib for the treatment of adult patients with moderate-to-severe chronic plaque psoriasis. This three-period study showed that tofacitinib, as a 5-mg or 10-mg pill taken twice daily, met its two primary efficacy endpoints. The safety profile of tofacitinib in OPT Retreatment was consistent with previous studies, and there were no new safety findings in this trial.